UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~April~~June 3026, 2026

EMERGENT BIOSOLUTIONS INC.

(Exact name of registrant as specified in its charter)

Delaware

001-33137

14-1902018

(State or other jurisdiction

(Commission File Number)

(IRS Employer

of incorporation)

Identification No.)

300 Professional Drive,

Gaithersburg, Maryland 20879

(Address of principal executive offices, including zip code)

(240) 631-3200

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	EBS	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 21.~~02.~~01 Entry ~~Results~~into ofa ~~Operations~~Material ~~and~~Definitive ~~Financial Condition.~~Agreement

On ~~April~~June 3026, 2026 , Emergent BioSolutions Inc. (the "“Company",” including its wholly-owned subsidiaries, “Emergent”), ~~issued~~through its wholly-owned subsidiary, Emergent Product Development Gaithersburg Inc., received a ~~press~~contract ~~release~~modification (from the ~~"Press~~Office ~~Release"~~of the Assistant Secretary for Preparedness and Response (“ASPR”), ~~announcing~~an ~~its~~agency ~~financial~~of the U.S. Department of Health and ~~operating~~Human ~~results~~Services (“Modification No. 15”), exercising Option Year 7 for ~~the~~Emergent ~~quarter~~to ~~ended~~supply ~~March~~ACAM2000® 31(Smallpox (Vaccinia) Vaccine, ~~2026~~Live) to the U.S. Agovernment ~~copy~~under ofEmergent’s existing 10-year contract with ASPR (the ~~Press~~“ACAM2000 ~~Release~~Contract”). isModification ~~furnished~~No. as15 ~~Exhibit~~is 99valued at $52.17 million and requires Emergent to ~~this~~deliver ~~Current~~doses ~~Report~~of onACAM2000®, ~~Form~~ancillaries ~~8-K~~as ~~(this~~well ~~"Form~~as ~~8-K")~~diluent replacement lots to the U.S. government in June 2026, and isany ~~incorporated~~remaining ~~herein~~balance of diluent by ~~reference~~December 2026.

~~Item~~The 7preceding description of Modification 15 does not purport to be complete and is qualified in its entirety by reference to the full text of Modification 15.01 A copy of Modification 15 is expected to be filed as an exhibit to the Company’s next Quarterly Report on Form 10-Q. ~~Regulation~~The FDACAM2000 ~~Disclosure~~Contract is filed as a material agreement of Emergent as Exhibit 10.48 with the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019.

OnItem ~~April 30, 2026, the Company will host a conference call to discuss its financial and operating results for the quarter ended March 31, 2026~~7. ~~The~~01 ~~Company~~Regulation ~~will~~FD ~~use presentation materials in connection with this conference call (the "Earnings Call Slides"), which will be posted on the Company’s website at www~~Disclosure.emergentbiosolutions.com. A copy of the Earnings Call Slides is furnished as Exhibit 99.2 to this Form 8-K and is incorporated herein by reference. Information on the Company's website is not, and will not be deemed to be, a part of this Form 8-K or incorporated into any other filings the Company may make with the U.S. Securities and Exchange Commission.

~~The~~On ~~information~~June ~~contained~~29, in2026, ~~Items~~the ~~2.02~~Company ~~and~~issued ~~7.01~~a ofpress ~~this~~release ~~Form~~announcing ~~8-K~~Modification ~~and Exhibits 99~~No.1 ~~and 99~~15.2 ~~attached~~A ~~hereto,~~copy ~~shall not be deemed "filed" for purposes~~ of ~~Section 18 of~~ the ~~Securities~~press ~~Exchange~~release ~~Act~~is offurnished ~~1934,~~ as ~~amended~~Exhibit ~~(the~~99.1 ~~"Exchange Act"), or otherwise be subject~~ to ~~the~~this ~~liabilities~~Current ofReport ~~that~~on ~~section,~~Form ~~nor~~8-K ~~shall~~and itis ~~be deemed~~ incorporated by reference ~~in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing~~herein.

The information contained in this Item 97.01~~. Financial~~ ~~Statements~~shall ~~and~~not ~~Exhibits~~be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.						Description
99.1						Press release issued by Emergent BioSolutions Inc. on ~~April~~June 3029, 2026.
99.2						Earnings Call Slides, dated April 30, 2026.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	EMERGENT BIOSOLUTIONS INC.
Dated: April 30, 2026	By:	/s/ RICHARD S. LINDAHL
Dated: June 29, 2026	By:	/s/ RICHARD S. LINDAHL
		Name: Richard S. LindahlTitle: Executive Vice President, Chief Financial Officer

Filing Compare · Emergent BioSolutions Inc.